Sermorelin side effects: what the clinical trials reported

This article reviews sermorelin side effects reported in the historical clinical program for Geref and in published clinical literature, with regulatory context current to November 17, 2026.

Trial readout7 min read

Key takeaway

FDA review material states that about 16% of pediatric Geref trial participants experienced self-limited, transient injection-site pain, redness or swelling. Other treatment-related events each occurred in fewer than 1% of participants. FDA records also state that Geref was discontinued and that its withdrawal from sale was not for reasons of safety or effectiveness.

At a glance

Article typeTrial readout
Main guideSermorelin: complete guide
ClassGrowth hormone axis
Body systemsEndocrine & metabolism
Studies cited3 in this article · 22 across 4 articles on Sermorelin
Related productsGHRH analogs and GH secretagogues

Sermorelin side effects described in historical clinical records included temporary injection-site pain, redness or swelling. Facial flushing, headache, dizziness, somnolence, hyperactivity, difficulty swallowing and urticaria were reported less often in pediatric clinical trials. These findings come from a historical prescription product program and should not be treated as a safety profile for unapproved research materials.

Quick answer: Sermorelin side effects reported in historical Geref studies most commonly included temporary injection-site pain, redness or swelling. FDA review material reports these events in about 16% of pediatric participants. Facial flushing, headache, dizziness, somnolence, hyperactivity, dysphagia and urticaria each occurred in fewer than 1%. These data do not establish the safety of current research-grade products.

What did sermorelin studies report?

Sermorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH). It was historically marketed as Geref in the United States. Geref was developed for diagnostic assessment of growth hormone deficiency and for treatment of growth failure in children with growth hormone deficiency. The FDA review of tesamorelin includes a historical summary of Geref safety information and the pediatric clinical program (FDA, Egrifta Medical Review, 2010).

In that FDA review, the agency described the Geref Diagnostic safety experience as including temporary injection-site pain, redness or swelling, facial flushing, pallor, headache, nausea, vomiting, altered taste and chest tightness. The review describes these events as rare after use of Geref Diagnostic. It does not provide a percentage for each diagnostic-use event in that summary (FDA, Egrifta Medical Review, 2010).

For Geref Pediatric, the FDA review states that the safety profile was similar. It identifies injection-site pain, redness or swelling as the most common treatment-related adverse event. These reactions were self-limited and transient and occurred in approximately 16% of patients in the clinical trials. Other treatment-related events each had an occurrence rate below 1% (FDA, Egrifta Medical Review, 2010).

The patient population matters. Geref Pediatric was studied in children with growth hormone deficiency. These rates do not automatically apply to adults, other conditions or unapproved products sold under a sermorelin label. The historical Geref diagnostic product was used in a different setting from the pediatric treatment product.

Which sermorelin side effects were most common?

The most frequently reported treatment-related events in the historical pediatric Geref clinical program were local reactions at the injection site. FDA review material places the approximate rate at 16%. The reactions included pain, redness or swelling and were described as self-limited and transient (FDA, Egrifta Medical Review, 2010).

The same review lists facial flushing, headache, dizziness, somnolence, hyperactivity, dysphagia and urticaria as other treatment-related events. Each had an occurrence rate below 1% in the cited pediatric studies. The FDA summary does not provide a separate percentage for every individual event, so no finer ranking is possible from that source (FDA, Egrifta Medical Review, 2010).

A 1999 review of sermorelin in children with idiopathic growth hormone deficiency similarly described transient facial flushing and injection-site pain as the most commonly reported adverse events. The review summarized historical studies and is useful as context, while the primary rate above comes from FDA review material (Prakash & Goa, 1999).

An archived Irish Summary of Product Characteristics for Geref 50 also listed facial heat, facial flushing and injection-site pain as occasional adverse events that usually disappeared within minutes. This is historical non-U.S. product information, not a current U.S. prescribing label (Irish Medicines Board, 2004).

Table 1

Which sermorelin side effects were most common

Historical study settingParticipantsReported adverse eventReported frequency
Geref Pediatric clinical trialsChildren treated for growth hormone deficiencyInjection-site pain, redness or swellingApproximately 16%; self-limited and transient
Geref Pediatric clinical trialsChildren treated for growth hormone deficiencyFacial flushing, headache, dizziness, somnolence, hyperactivity, dysphagia and urticariaEach below 1%
Geref Diagnostic usePatients undergoing diagnostic assessmentInjection-site symptoms, flushing, pallor, headache, nausea, vomiting, altered taste and chest tightnessDescribed as rare; separate percentages not provided in the FDA summary

What did longer-term pediatric studies report?

A multicenter, open-label Geref International Study Group report followed previously untreated prepubertal children with growth hormone deficiency. The study included 110 children treated for up to one year. The publication reported increased height velocity during the study period and stated that no adverse changes were found in general biochemical or hormonal analyses. It described the treatment as generally well tolerated (Geref International Study Group, 1996).

That publication is useful because it describes the population and length of follow-up. However, the abstract does not provide a full event-by-event table with rates for every possible adverse reaction. It should not be used to invent percentages that the paper did not report.

These distinctions matter because the growth hormone-releasing hormone family includes different peptides and formulations. An event reported with one molecule should not be assigned automatically to another.

What is sermorelin's FDA status?

The FDA's Orphan Drug Designations and Approvals database records marketing approval for Geref Pediatric in 1997 for the treatment of idiopathic or organic growth hormone deficiency in children with growth failure. FDA records also list Geref Diagnostic as an earlier approved product (FDA, Orphan Drug Designations and Approvals).

Geref was later discontinued. In a 2013 Federal Register notice, FDA determined that the relevant Geref products were not withdrawn from sale for reasons of safety or effectiveness. The notice explained that abbreviated new drug applications could potentially be approved if all other legal and regulatory requirements were met. The finding does not mean that every currently marketed product labeled sermorelin is FDA-approved (FDA, Federal Register, March 4, 2013).

FDA's archival approval package identifies Geref as sermorelin acetate and documents a supplemental approval under NDA 19-863 in 1991. A later review of growth hormone secretagogues reports that marketed sermorelin was discontinued in 2008 because of manufacturing difficulties, not safety concerns (FDA, Geref NDA 19-863/S001 Approval Package; Ishida et al., 2020). Current FDA product listings should be checked before making any claim about an available approved sermorelin product.

What can historical side-effect reports tell us about research materials?

Historical clinical trials can describe adverse events observed with the specific product, formulation, population and study conditions tested. They cannot establish the safety of a different product that has not undergone comparable clinical evaluation.

Research-use materials are not automatically equivalent to an FDA-approved prescription product. Differences in identity, purity, impurities, formulation, manufacturing controls and storage may affect the material being evaluated. Historical Geref trial rates should not be used as a guarantee or prediction for current research products.

The available evidence also does not establish a complete long-term safety profile for every population. Pediatric growth hormone deficiency, diagnostic testing and adult research settings are different contexts. The absence of a reported event in a small or historical study is not proof that the event cannot occur.

Frequently asked questions

What are the most common sermorelin side effects reported in trials?

Historical Geref Pediatric studies most commonly reported temporary injection-site pain, redness or swelling. The FDA review reports these events in approximately 16% of pediatric participants.

Does sermorelin cause flushing or headaches?

Facial flushing and headache were reported as treatment-related events in historical Geref Pediatric studies. Each occurred in fewer than 1% of participants in the FDA summary.

Was sermorelin studied in children?

Yes. Geref Pediatric was studied in children with growth hormone deficiency. The FDA review describes the adverse-event findings from that clinical program.

Is sermorelin FDA approved today?

Geref products were historically approved but later discontinued. FDA determined in 2013 that their withdrawal from sale was not for safety or effectiveness reasons. That determination does not approve every sermorelin product currently offered.

Do historical Geref side-effect rates apply to research-grade sermorelin?

No. The historical data describe particular prescription products and study populations. They do not establish the safety profile of a different research material.

For related company information, visit the Vitrapep research library or the Vitrapep website. The sermorelin complete guide provides a companion overview.

What to know now

  • Historical Geref Pediatric studies most commonly reported temporary injection-site reactions, at approximately 16% of participants.
  • Other treatment-related events listed in FDA review material each occurred in fewer than 1% of pediatric participants.
  • Geref was discontinued, and FDA determined that its withdrawal from sale was not for safety or effectiveness reasons.

What we’re watching

  • Any current FDA listing or approval involving sermorelin should be checked against the agency's live product databases before publication updates.
  • New controlled studies with clearly defined products and populations would be needed to characterize adverse events in contemporary research settings. No upcoming sermorelin readout was verified for this draft.

Also in the library

More for endocrine & metabolism

All 38 compounds for endocrine & metabolism

Sources: U.S. Food and Drug Administration 2010, Egrifta (tesamorelin acetate) Medical Review; Geref International Study Group 1996, Journal of Clinical Endocrinology & Metabolism; Prakash 1999, BioDrugs, 12; U.S. Food and Drug Administration 2013, Federal Register, 78; U.S. Food and Drug Administration. (n.d.). Search Orphan Drug Designations and Approvals: Sermorelin acetate (Geref) . https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687, Search Orphan Drug Designations and Approvals: Sermorelin acetate (Geref); Irish Medicines Board 2004, Geref 50: Summary of Product Characteristics; U.S. Food and Drug Administration 1991, Geref (sermorelin acetate for injection), NDA 19-863/S001 approval package; Ishida 2020, JCSM Rapid Communications, 3. All 8 citations

Back to the research library

References

  1. U.S. Food and Drug Administration. (2010). Egrifta (tesamorelin acetate) Medical Review. Includes historical Geref diagnostic and pediatric safety information. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022505Orig1s000MedR.pdf
  2. Geref International Study Group. (1996). Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Journal of Clinical Endocrinology & Metabolism. https://pubmed.ncbi.nlm.nih.gov/8772599/
  3. Prakash, A., & Goa, K. L. (1999). Sermorelin: A review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs, 12(2), 139–157. https://doi.org/10.2165/00063030-199912020-00007
  4. U.S. Food and Drug Administration. (2013). Determination that GEREF (sermorelin acetate) injection was not withdrawn from sale for reasons of safety or effectiveness. Federal Register, 78(42), 14095–14096. https://www.govinfo.gov/content/pkg/FR-2013-03-04/html/2013-04827.htm
  5. U.S. Food and Drug Administration. (n.d.). Search Orphan Drug Designations and Approvals: Sermorelin acetate (Geref). https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687
  6. Irish Medicines Board. (2004). Geref 50: Summary of Product Characteristics. https://assets.hpra.ie/products/Human/16600/LicenseSPC_PA0285-006-001_13072006155719.pdf
  7. U.S. Food and Drug Administration. (1991). Geref (sermorelin acetate for injection), NDA 19-863/S001 approval package. https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019863_S001_GEREF.pdf
  8. Ishida, J., Saitoh, M., Ebner, N., Springer, J., Anker, S. D., & von Haehling, S. (2020). Growth hormone secretagogues: History, mechanism of action, and clinical development. JCSM Rapid Communications, 3(1), 25–37. https://doi.org/10.1002/rco2.9